: Sedentary lifestyle has become a great concern to human health. City parks play a great role in the solution of this problem, but exposure to urban pollutants leads to the necessity to monitor environmental quality. Purpose of Study The aim of the study was to evaluate the possible cytotoxicity and genotoxicity of soil samples collected from Shumen city park using Allium cepa L.-test. Methods The following microscopic parameters were used: mitotic index, index of each phase of mitotic division, mitotic abnormalities and interphase cells with micronuclei or two nuclei. Findings and Results The decline of the mitotic activity and changes in the proportion of mitotic phases indicate soil cytotoxicity. Various mitotic abnormalities and binucleated cells revealed genotoxicity. Conclusions and Recommendations Established cytotoxicity and genotoxicity of soil revealed a potential health risk to park users. Further analyses should be provided, since positive results from Allium-test serve as an alarm.

The positive impact of numerous healthy behaviours on human health and wellbeing is well known. This study is the first to provide a comprehensive single healthy lifestyle score for a heterogeneous adult population in Bulgaria. The aim of this study is to make single healthy lifestyle score of the adults in Bulgaria. The survey was carried out with 714 randomly selected participants. A relative lifestyle score (RLS) was based on smoking status, alcohol consumption, physical activity, diet and BMI of respondents. The RLS ranged from 0 to 5, and a higher score representing a healthier lifestyle. The relationship between respondents’ healthy behaviours and demographic features was determined via the Pearson correlation coefficient. We found that the healthy lifestyle score of the participants is 2.98 of 5.00. The relatively lifestyle score of halves (45.94%) of them is in the range of 3.9-4.29. Regarding smoking and alcohol consumption, respondents' behaviour is the healthiest: 63.31% nonsmokers and 68.63% abstainers. Low physical activity and mixed diet patterns are the main risk factors for optimal healthy lifestyle achievement. We identified the demographic groups that are most vulnerable. Our study provides a possibility for reliable comparisons of healthy lifestyle levels among populations across countries. The RLS is a reliable tool for assessment a healthy lifestyle both of individuals and the community.

Background/Objectives: Triple-negative breast cancer (TNBC) is an aggressive and molecularly heterogeneous breast cancer subtype for which early detection remains clinically important. Circulating non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are being investigated as blood-based biomarkers. This narrative review evaluates the clinical evidence for circulating ncRNAs as liquid-biopsy biomarkers for early TNBC detection, focusing on stage I–II disease, diagnostic performance, comparator selection, and validation. Methods: Peer-reviewed studies published between 2009 and October 2026 were identified primarily through PubMed/MEDLINE searches, supplemented by Google Scholar searches, with particular attention to disease stage, comparator populations, diagnostic performance, and validation status. Results: Among the ncRNA classes reviewed, circulating miRNAs provide the most directly relevant, although still limited, clinical evidence for early-stage TNBC detection, whereas evidence for lncRNAs and circRNAs remains predominantly exploratory and insufficiently validated for early-stage detection. Translation is limited by small, heterogeneous cohorts, analytical variability, and insufficient independent and prospective validation. Conclusions: High diagnostic accuracy in selected cohorts does not establish clinical readiness. Standardized analytical workflows, independent multicenter validation, prospective evaluation in intended-use populations, and integration with imaging and clinical assessment are needed before circulating ncRNA signatures can be considered for clinical use.

The therapeutic efficacy of anti-HER2 monoclonal antibodies in breast cancer has traditionally been attributed to direct inhibition of signaling and antibody-dependent cellular cytotoxicity (ADCC). Recent evidence, however, has established complement activation through the classical pathway as a possible adjunct mechanism underlying the synergistic activity of the trastuzumab and pertuzumab combination. This synergy is mediated by complement-dependent cytotoxicity (CDC) and complement-dependent cellular phagocytosis (CDCP), and is lost upon C1q deletion in preclinical models. Tumor cells evade complement-mediated killing through overexpression of membrane-bound complement regulatory proteins (mCRPs), particularly CD55 and CD59, which correlate with shorter disease-free survival in patients treated with trastuzumab. C1q itself plays a dual, context-dependent role: it acts as a complement-independent tumor suppressor in HER2-positive breast cancer while promoting tumor progression in most other malignancies. Emerging therapeutic strategies, including biparatopic antibodies such as zanidatamab, complement-redirecting immunoconjugates, and mCRP-targeting approaches, aim to overcome complement resistance and enhance antitumor immunity. On this basis, we propose that HER2-positive breast cancer represents a conditionally complement-protective tumor, in which the balance between antibody-directed complement activation and mCRP-mediated evasion determines treatment outcome. This review evaluates the current evidence linking complement to anti-HER2 therapy and highlights future directions for successful treatment.